Figure 2
Figure 2. Preventive and therapeutic effect of ALX-0681 on the markers of thrombocytopenia and schistocytic hemolytic anemia. Platelet counts (109/L; A), haptoglobin levels (g/L; B), schistocyte counts (%; C), and LDH levels (U/L; D) were measured in control (●; n = 4), preventive (□; n = 4), and therapeutic (; n = 4) animals as a function of time (days). Results were analyzed with a mixed model and a posthoc test with Tukey multiple comparison adjustment. Data are represented as means ± SD. “a” indicates a significant difference between control and preventive animals (P < .05); “b,” significant difference between control and preventive animals (P < .001); “c,” significant difference between control and therapeutic animals (P < .05); and “d,” significant difference between control and therapeutic animals (P < .001).

Preventive and therapeutic effect of ALX-0681 on the markers of thrombocytopenia and schistocytic hemolytic anemia. Platelet counts (109/L; A), haptoglobin levels (g/L; B), schistocyte counts (%; C), and LDH levels (U/L; D) were measured in control (●; n = 4), preventive (□; n = 4), and therapeutic (; n = 4) animals as a function of time (days). Results were analyzed with a mixed model and a posthoc test with Tukey multiple comparison adjustment. Data are represented as means ± SD. “a” indicates a significant difference between control and preventive animals (P < .05); “b,” significant difference between control and preventive animals (P < .001); “c,” significant difference between control and therapeutic animals (P < .05); and “d,” significant difference between control and therapeutic animals (P < .001).

Close Modal

or Create an Account

Close Modal
Close Modal